Required section · Section 2 of 6
Four pathways, four drugs, one shared endpoint
Platelet activation runs through several receptor pathways that converge on the same physical event: platelets cross-linking through fibrinogen to form an aggregate. Four of these pathways carry the antiplatelet drugs most often encountered on the bench. Aspirin acetylates cyclooxygenase-1 (COX-1) irreversibly, blocking thromboxane A2 formation for the remaining lifespan of every platelet it reaches. Clopidogrel's active metabolite irreversibly blocks the ADP/P2Y12 receptor, which reduces the downstream activation of the fibrinogen receptor.
Eptifibatide works differently: it reversibly blocks the fibrinogen receptor itself, glycoprotein (GP) IIb/IIIa, preventing fibrinogen and von Willebrand factor from binding regardless of which upstream pathway tried to activate it. Cilostazol acts further upstream in a different way, inhibiting phosphodiesterase III (PDE III) and raising intracellular cyclic AMP, which dampens platelet activation broadly rather than blocking one receptor.
Two functional agonists used in light-transmission aggregometry map onto two of these pathways. Arachidonic acid stimulates the COX-1/thromboxane branch, making it the agonist most aligned with aspirin exposure. ADP stimulates the P2Y12 branch, making it the agonist most aligned with residual reactivity after a P2Y12 inhibitor such as clopidogrel. GP IIb/IIIa blockade has no single universal monitoring agonist or cutoff, because eptifibatide blocks the convergence point directly rather than one upstream receptor.
None of platelet count, prothrombin time (PT), or activated partial thromboplastin time (aPTT) test any of these four pathways. Platelet count is a cell count, not a signaling assay. PT and aPTT are plasma clotting assays built to assess coagulation factors, not platelet receptor function. A normal result on any of these three says nothing about whether COX-1, P2Y12, GP IIb/IIIa, or PDE III activity is intact or blocked.
Knowing a drug's mechanism tells you which functional agonist could reveal its effect; it does not by itself tell you that testing is indicated.
| Drug | Class | Platelet pathway/target | Documented effect |
|---|---|---|---|
| Aspirin | COX inhibitor | Cyclooxygenase-1 / thromboxane A2 | Irreversibly inhibits COX-1, blocking thromboxane A2 formation for the platelet's lifespan |
| Clopidogrel | P2Y12 inhibitor | ADP / P2Y12 receptor | Active metabolite irreversibly blocks P2Y12, reducing downstream GP IIb/IIIa activation |
| Eptifibatide | GP IIb/IIIa inhibitor | Fibrinogen receptor (GP IIb/IIIa) | Reversibly blocks GP IIb/IIIa, preventing fibrinogen and von Willebrand factor binding |
| Cilostazol | PDE III inhibitor | Phosphodiesterase III / cyclic AMP | Inhibits PDE III, raising platelet cyclic AMP and dampening activation |
From receptor binding to the signal an instrument actually detects, with the point where each drug intervenes.
Agonist binds its platelet receptor
Collagen, ADP, thrombin, or arachidonic acid engages a specific platelet surface receptor. Aspirin blocks the arachidonic-acid/COX-1 branch and clopidogrel's active metabolite blocks the ADP/P2Y12 branch at this step.
Intracellular signaling amplifies the response
Receptor engagement raises intracellular calcium and lowers cyclic AMP. Cilostazol opposes this by inhibiting phosphodiesterase III, keeping cyclic AMP elevated and dampening amplification.
GP IIb/IIIa converts to its active form
The fibrinogen receptor converts to a high-affinity state. Eptifibatide reversibly blocks this receptor directly, independent of which upstream pathway drove activation.
Aggregation produces a measurable signal
Platelets cross-link through fibrinogen and clump. This physical aggregation is the event that light-transmission aggregometry, whole-blood impedance, and cartridge assays each detect through a different signal.
Knowledge checks
Reading and checks are open. Sign in only to save.
Knowledge check 1
Knowledge check 2
Section status
Finish this section
Reading and checks are open. Sign in only to save.
The module finishes after every required section is marked done and every check in those sections is correct.